The latest research news in genetics and genomics.
The researchers at the Royal College of Surgeons Ireland recently received €1.3 million from Wellcome Trust to support the development of the blood-based test.
Fluidigm CEO Chris Linthwaite said the company aims to further penetrate the diagnostic and clinical markets with both its microfluidics and mass cytometry businesses.
The firm also announced a COVID-19 testing deal with George Mason University and a CyTOF supply and distribution agreement with Zhejiang PuLuoTing Health Technology in China.
The company said it has priced a public offering of 3,571,428 shares of its common stock at $70.00 per share.
The company posted a Q4 net income of $2.50 billion, or $6.24 per share, up sharply from $1.00 billion, or $2.49 per share, during the same quarter last year.
